BIZARRE: Evusheld - You Need To See This

Former vaccines tsar describes ‘open warfare’ within UK government during Covid pandemic

Dame Kate Bingham, who led the vaccine taskforce in 2020, said the clinically vulnerable were deprioritised and goals were not followed

The Guardian - UK · Jan 21, 2025

Covid-19 drug Evusheld not recommended for NHS use

The National Institute for Health and Care Excellence (NICE) said there is no clinical evidence that it protects against existing coronavirus variants

Wales Online · Feb 16, 2023

FDA revokes authorization for key anti-COVID-19 drug, a blow for vulnerable Americans

The Food and Drug Administration has withdrawn its provisional support for the use of Evusheld, a medication that was once a valuable tool for preventing patients with weakened immune systems from becoming severely ill with COVID-19.

Los Angeles Times · Jan 28, 2023

'There can't be different rules': why COVID drugs are sitting in stockpile

Health services should do more to help transplant patients get access to COVID drug Evusheld.

Newcastle Herald · Jul 17, 2022

AstraZeneca boss calls for UK to provide new Covid-19 medicine to the vulnerable

Pharmaceutical CEO says it’s ‘sad’ that UK has failed to order Evusheld for the immunosuppressed

The Guardian - UK · Apr 29, 2022

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Benzinga · Apr 29, 2022

The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga · Apr 21, 2022

AstraZeneca's COVID-19 Antibody Provides Protection For At Least Six Months In High-Risk Individuals

AstraZeneca plc (NASDAQ:AZN) shared detailed results from the PROVENT Phase 3 pre-exposure prophylaxis (prevention) trial of Evusheld (tixagevimab and cilgavimab), formerly AZD7442. The data showed that Evusheld reduced the risk of developing symptomatic COVID-19 by 77% in the primary analysis and 83% in the six-month follow-up analysis, compared to placebo.  There were no…

Benzinga · Apr 21, 2022

Evusheld procurement plan gets CCSA approval

The Centre for Covid-19 Situation Administration (CCSA) has approved a plan to procure a long-acting coronavirus antibody cocktail for people with poor immune systems who cannot be vaccinated.

Bangkok Post · Apr 10, 2022

Can evusheld treat Covid-19? An infectious disease expert answers 7 key questions

Infectious disease physician Patrick Jackson of the University of Virginia explains how it works, who’s eligible and why some patients are having difficulties accessing it.

Inverse · Apr 2, 2022